Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 27;9(11):1247. doi: 10.3390/vaccines9111247

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Flow cytometry analysis of myeloid cells in the tumors treated with SFV/IFNg, SFV/Luc, or PBS in an orthotopic 4T1 mouse breast cancer model. Mice were treated as shown in Figure 6d. Resected tumors were homogenized to obtain a single cell suspension, which was used for immunostaining with antibodies against surface markers (CD11b, CD206, MHCII, CD38) and intracellular markers (Arginase 1, iNOs) in one mixture. (a) Percentages of surface markers CD11b, CD11b (high), and double-positive CD206/CD11b. (b) Percentages of surface markers MHCII (high) and CD11b⁺MHCII⁻. (c) Percentages of surface markers CD11b⁺/CD38⁺ and CD11b⁻/CD38⁺ (d) Percentages of intracellular markers (Arginase 1; iNOs, inducible NO synthase); representative images of Arginase 1 and iNOs gating in the CD11b⁺ population are shown. Bars represent the means ± SD (n = 5); * p < 0.05; ** p < 0.01; ns—nonsignificant.